Lantheus Holdings, Inc.

Listed Company

LNTHCIK 0001521036NasdaqLarge AcceleratedIn Vitro & In Vivo Diagnostic SubstancesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.54B

Net Income

$233.56M

Total Assets

$2.23B

Equity

$1.09B

Shares Out

64.61M

Op. Cash Flow

$390.14M

Business

Lantheus Holdings, Inc. is a radiopharmaceutical-focused healthcare company that develops, manufactures and commercializes diagnostic and therapeutic imaging agents and related digital and biomarker solutions. Its main products and services include radiopharmaceutical oncology agents (e.g., PYLARIFY), precision diagnostics (e.g., DEFINITY, TechneLite, NEUROLITE, CARDIOLITE, Xenon-133), clinical-stage imaging candidates (e.g., MK-6240, NAV-4694) and digital tools and biomarker partnerships (aBSI, aPROMISE/PYLARIFY AI). The company organizes its activities across Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue segments. It sells primarily in the United States to hospitals, radiopharmacies and diagnostic facilities and distributes internationally through direct and third-party channels in Canada, Europe, Asia-Pacific, Australia, Central and South America.

Summary from filing dated 2025-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Noncash impairment	1,542	1,534	1,296	935	425
Cost of goods sold	600	546	587	353	238
Gross profit	942	988	710	582	188
Sales and marketing	179	178	142	100	68
General and administrative	275	194	125	134	150
Research and development	177	168	78	312	45
Total operating expenses	631	540	345	546	264
Gain on sale of assets	0	8	0	0	15
Operating income	311	457	365	36	−61
Interest expense	20	20	20	7	—
Investment in equity securities - unrealized loss	9	44	0	0	—
Other income, net	−31	−37	−66	2	7
Income before income taxes	314	431	411	27	−75
Income tax expense	80	119	84	−1	−4
Net income	234	312	327	28	−71
Basic (in dollars per share)	3.46	4.52	4.79	0.41	−1.06
Diluted (in dollars per share)	3.41	4.36	4.65	0.4	−1.06
Basic (in shares)	67	69	68	68	67
Diluted (in shares)	68	72	70	71	67

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	359	913	714	416	99
Accounts receivable, net	359	321	284	213	89
Inventory, net	65	68	64	35	35
Income tax receivable	15	8	—	—	—
Other current assets	21	16	17	13	13
Assets held for sale	81	0	7	0	0
Total current assets	900	1,327	1,086	678	236
Investment in equity securities	42	39	0	—	—
Property, plant and equipment, net	164	177	147	122	117
Intangibles, net	723	162	152	315	349
Goodwill	240	61	61	61	61
Deferred tax assets, net	109	170	150	111	63
Other long-term assets	50	44	55	34	39
Total assets	2,227	1,980	1,651	1,321	864
Current portion of long-term debt and other borrowings	738,000	974,000	823,000	354,000	12
Accounts payable	43	35	41	21	21
Accrued expenses and other current liabilities	267	205	145	127	58
Liabilities held for sale	22	0	—	—	0
Total current liabilities	333	241	187	248	90
Asset retirement obligations	138,000	23	23	23	21
Long-term debt and other borrowings, net of current portion	569	565	562	558	—
Long-term deferred tax liabilities	54	0	—	—	—
Long-term contingent consideration liabilities	73	0	—	—	—
Other long-term liabilities	108	63	63	46	125
Total liabilities	1,138	892	835	874	399
Commitments and contingencies (Note 17)	—	—	—	—	—
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)	0	0	0	0	0
Common stock ($0.01 par value; 250,000 shares authorized; 71,827 and 70,905 shares issued; 64,586 and 68,450 shares outstanding at December 31, 2025, and December 31, 2024, respectively)	718,000	709,000	699,000	689,000	677,000
Additional paid-in capital	888	818	758	716	685
Treasury stock at cost; 7,241 shares and 2,455 shares and 2,455 shares at December 31, 2025 and December 31, 2024, respectively	−477	−175	−75	−75	—
Retained earnings	680	446	134	−193	−221
Accumulated other comprehensive loss	−1	−2	−1	−1	−485,000
Total stockholders equity	1,090	1,088	816	447	464
Total liabilities and stockholders equity	2,227	1,980	1,651	1,321	864

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation, amortization and accretion	70	65	60	48	42
Impairment of long-lived assets	0	0	138	0	10
Adjustment to the fair value of asset retirement obligation	−5	0	0	—	—
Amortization of debt-related costs	4	4	4	1	676,000
Change in fair value of contingent assets and liabilities	1	−3	−9	—	—
Inventory adjustments	2	−904,000	8	7	4
Stock-based compensation	86	76	51	29	16
Gain on disposal of assets	0	−8	0	0	−15
Gain on sale of RELISTOR licensed intangible asset	−5	0	−52	—	—
Unrealized loss on investment in equity securities	9	44	0	0	—
Charges incurred pursuant to acquired in-process research and development	11	66	0	260	0
Deferred taxes	22	−30	−56	−48	4
Long-term indemnification receivable	0	0	4	10	7
Long-term income tax payable and other long-term liabilities	246,000	5	−3	−12	−8
Other, net	5	12	5	4	3
Accounts receivable	−18	−38	−69	−128	−33
Inventory	−9	−3	−36	−8	−4
Other current and noncurrent assets	−5	4	−2	—	—
Accounts payable	−2	−9	17	301,000	5
Accrued expenses and other current and long-term liabilities	−9	47	−81	64	16
Net cash provided by operating activities	390	545	305	282	54
Capital expenditures	−36	−52	−47	−18	−12
Acquisition of in-process research and development	−5	0	0	—	—
Proceeds from sale of assets	0	18	98	2	16
Acquisition of assets, net	0	−81	−45	−260	—
Purchases of investment in equity securities	−10	−83	0	0	—
Acquisition of exclusive license option	0	−28	0	0	—
Net cash (used in) provided by investing activities	−627	−226	6	−277	4
Payments of long-term debt and other borrowings	−1	−318,000	−717,000	−175	−43
Deferred financing costs	0	−2	0	−2	0
Proceeds from stock option exercises	7	3	4	8	5
Contingent value rights settlement	0	0	−4	0	0
Proceeds from employee stock purchase plan	4	3	2	—	—
Payments for minimum statutory tax withholding related to net share settlement of equity awards	−26	−23	−14	−8	−2
Repurchase of common stock	−300	−100	0	−75	0
Net cash used in financing activities	−317	−119	−13	312	−39
Effect of exchange rate changes on cash, cash equivalents and restricted cash	−49,000	−998,000	−93,000	−335,000	−310,000
Net (decrease) increase in cash, cash equivalents and restricted cash	−554	199	298	317	18
Interest	15	15	15	5	6
Income taxes , net of refunds of $28, $2,688 and $25, respectively	69	154	152	54	215,000
Additions of property, plant and equipment included in liabilities	3	5	7	2	1
In-process research and development included in liabilities	6	0	0	—	—
Contingent consideration liabilities related to acquisitions	97	0	0	—	—
Lease liability settled through transfer of lease	0	762,000	0	0	—
Modification of lease agreement	6	0	0	—	—
Right-of-use asset obtained in exchange for operating lease liabilities	3	63,000	29	11	683,000
Right-of-use asset obtained in exchange for finance lease obligation	711,000	514,000	2	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro